Email this article 
Atopic dermatitis. When and how to use topical corticosteroiods?
- Authors: Fedenko ES1
-
Affiliations:
- Institute of Immunology
- Issue: Vol 9, No 3 (2012)
- Pages: 32-36
- Section: Articles
- Submitted: 10.03.2020
- Published: 15.12.2012
- URL: https://rusalljournal.ru/raj/article/view/708
- DOI: https://doi.org/10.36691/RJA708
- ID: 708
Cite item
Open Access
Access granted
Abstract
Atopic dermatitis is a disease characterized with increasing prevalence around the world. It has chronic relapsing course and has a negative impact on the quality of life. Topical steroids (TS) due to their mechanisms of action remain the mainstay of topical treatment for AD patients. At the same time, well known side effects associated with corticosteroid therapy, although seen more frequently with incorrect TS use, and rare with the use of modern TS, in some instances limit their use. That is a reason for proper selection of topical treatment algorythms of AD including emollients and other medications in addition to the TS.
Full Text
References
- Bieber T. Atopic Dermatitis. The N. Eng J. Med. 2008, v. 358, p. 1483-1494.
- Brown S., Irvine A. Atopic eczema and the filaggrin story. Semin Cutan Med. Surg. 2008, v. 27, p. 128-137.
- O’ Regan G.M., Irvine A.D. The role of filaggrin loss of function mutations in atopic dermatitis. Curr. Opin. Allergy Clin. Immunol. 2008, v. 8, p. 406-410.
- Elias P., Schmuth M. Abnormal skin barrier in the etiopathogenesis of atopic dermatitis. Curr. Opin. Allergy Clin. Immunol. 2009, v. 9, p. 437-446.
- Гущин И.С. Эпидермальный барьер и аллергия. Росс. Аллергол. Журн. 2007, № 2, с. 3-16.
- Akdis C.A. Review article Diagnosis and treatment of atopic dermatitis in children and adults: Europian Academy of Allergology and Clinical Immunology, American Academy of Allergy, Asthma and Immunology. PRACTAlL Consensus report. Allergy. 2006, v. 61, p. 969-987.
- Prakash A., Benfield P. Topical Mometasone. A Review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. Drugs. 1998, v. 55 (1), p. 145-163.
- Barnes P.J. New directions in allergic diseases: mechanism based antiinflammatory therapies. J. Allergy Clin. Immunology. 2000, v. 106, p. 5-16.
- Popper T.L., Gentles M.J., Kung T.T. et al. Structure activity relationship of series of novel topical corticosteroids. J. Steroid Biochem. Mol. Biol. 1987, v. 27 (4-6), p. 837-843.
- Sharon E. Jacob, MD, Tace Steele, BA. Corticosteroid classes: A quick reference guide including patch test substances and cross-reactivity. j. am. acad. dermatol. april 2006.
- Barton B.E., Jakway J.P., Smith S.R. Cytokine inhibition by a Novel Steroid, Mometason Furoat, Immunpharmacol. and Immunotoxicol. 1991, v. 3, p. 251-261.
- Емельянов А.В., Монахов К.Н. Молекулярные механизмы действия топических глюкокортикоидов: значение внегеномного эффекта. Укр. журн. дерматол., венерол. и косметол. 2003, № 3, c. 38-40.
- Vernon H.J., Lane A.T., Weston W. Comparison of mometasone furoate 0.1% cream and hydrocortisone 1.0% cream in the treatment of childhood atopic dermatitis. J. Am. Acad. Dermatol. 1991, Apr. 24, p. 603-607.
- Rafanelli A., Rafanelli S., Stanganelli I., et al. Mometasone furoate in the treatment of atopic dermatitis in children. J. Eur. Acad. Dermatol. Venereol. 1993, v. 2 (3), p. 225-230.
- Veien N.K., Holmp P., Larsen et al. Long-term, intermittent treatment of chronic hand eczema with mometasone furoate. British Journal of Dermatology. 1999, v. 140, p. 882-886.
Supplementary files
